Position in ABBV
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$29,005,032
+$13,001,466 QoQ
Shares Held
115,264
+56.6% QoQ
Ownership
0.007%
of shares outstanding
% of Portfolio
0.52%
of 13F equity value
Holder Rank
#496
of 4,153 holders
Holding Since
Dec 2023
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ABBV Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Brevan Howard Capital Management LP holds $180,596,811 across 9 Drug Manufacturers - General names. ABBV ranks #2 (16.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
77,094 | $92,468,863 | |
| 2 | ABBV |
AbbVie Inc.
This page
|
115,264 | $29,005,032 | |
| 3 | JNJ |
Johnson & Johnson
|
62,412 | $15,850,774 | |
| 4 | GILD |
Gilead Sciences, Inc.
|
123,329 | $15,581,385 | |
| 5 | BMY |
Bristol Myers Squibb Co
|
163,962 | $9,447,490 | |
| 6 | AMGN |
Amgen Inc
|
18,788 | $6,803,510 | |
| 7 | MRK |
Merck & Co., Inc.
|
50,031 | $6,428,983 | |
| 8 | AZN |
Astrazeneca PLC
|
20,152 | $3,821,222 |
All Filings in ABBV
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $29,005,032 | 115,264 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $16,003,566 | 73,583 | Shares | Defined | 2026-05-15 | |
| 2025-09-30 | $4,245,980 | 18,338 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $8,305,752 | 44,746 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $13,942,088 | 66,543 | Shares | Defined | 2025-05-15 | |
| 2024-09-30 | $5,098,933 | 25,820 | Shares | Defined | 2024-11-14 | |
| 2024-06-30 | $340,981 | 1,988 | Shares | Defined | 2024-08-14 | |
| 2023-12-31 | $1,972,303 | 12,727 | Shares | Defined | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||